[go: up one dir, main page]

CR8398A - Metodos para el tratamiento del asma - Google Patents

Metodos para el tratamiento del asma

Info

Publication number
CR8398A
CR8398A CR8398A CR8398A CR8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A
Authority
CR
Costa Rica
Prior art keywords
pkc
methods
agents
protein
asthma
Prior art date
Application number
CR8398A
Other languages
English (en)
Inventor
Chaudhary Divya
Kasaian Marion
Williams Cara
Marusic Suzana
M Czerwinski Robert
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8398A publication Critical patent/CR8398A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a metodos para agentes utiles para tratar asma. Los metodos incluyen seleccionar agentes que inhiben la produccion de una proteina PKC-0, asi como tambien agentes que inhiben la actividad de cinasa de una proteina PKC-0, o un fragmento funcional de la misma, en donde tales agentes son utiles para tratar el asma. Tambien se incluyen metodos para seleccionar agentes que inhiben la produccion de un producto de gen reportero codificado por una secuencia de acido nucleico operablemente ligada a un promotor de PKC-0. Tambien se describen metodos para tratar asma que incluyen, administrar un agente que inhibe la produccion de una proteina de PKC-0 funcional o la actividad de cinasa de una proteina de PKC-0 o un fragmento funcional de la misma. Tambien se describe una celula mastil aislada que carece de la expresion de una PKC-0 endogena.
CR8398A 2003-12-24 2006-05-11 Metodos para el tratamiento del asma CR8398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53252503P 2003-12-24 2003-12-24
US58941504P 2004-07-20 2004-07-20

Publications (1)

Publication Number Publication Date
CR8398A true CR8398A (es) 2006-10-06

Family

ID=34743021

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8398A CR8398A (es) 2003-12-24 2006-05-11 Metodos para el tratamiento del asma

Country Status (14)

Country Link
US (1) US20050164323A1 (es)
EP (1) EP1702214A4 (es)
JP (1) JP2007525210A (es)
KR (1) KR20060127415A (es)
AU (1) AU2004308441A1 (es)
BR (1) BRPI0417212A (es)
CA (1) CA2545722A1 (es)
CR (1) CR8398A (es)
EC (1) ECSP066672A (es)
IL (1) IL175351A0 (es)
MX (1) MXPA06007094A (es)
NO (1) NO20062496L (es)
RU (1) RU2006126704A (es)
WO (1) WO2005062918A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
AU2004263009B2 (en) 2003-08-07 2009-12-24 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
DE102005020754B3 (de) * 2005-05-02 2007-01-11 Altana Pharma Ag Zelluläres Assayverfahren zur Identifizierung von PKCtheta-Inhibitoren
ZA200802546B (en) * 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
ES2405364T3 (es) * 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
WO2008082982A1 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Improved assay for immunosuppressant drugs
JP5319549B2 (ja) * 2006-12-29 2013-10-16 アボット・ラボラトリーズ 溶液内捕捉イムノアッセイで使用する非変性細胞溶解試薬
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
CA2685123A1 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2185184A2 (en) * 2007-07-30 2010-05-19 HealOr Ltd. Pharmaceutical composition for treating wounds and related methods
WO2010017473A2 (en) * 2008-08-07 2010-02-11 The Salk Institute For Biological Studies Method of identifying ikk2 activators or inhibitors
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
WO2011068898A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8710223B2 (en) 2010-07-21 2014-04-29 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
RU2526146C2 (ru) * 2012-09-27 2014-08-20 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ профилактики и лечения бронхиальной астмы, осложняющих ее респираторных вирусных инфекций и других воспалительных заболеваний дыхательных путей
WO2014089112A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
EP2970275B1 (en) 2013-03-14 2018-05-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5574094A (en) * 1992-11-30 1994-06-22 Biosignal Kutato-Fejleszto Kft. Polyunsaturated fatty acyl-peptide composition
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU2481800A (en) * 1998-12-17 2000-07-03 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methodsof making and using them
SE9902387D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New pharmaceutically active compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
WO2001048236A1 (en) * 1999-12-27 2001-07-05 La Jolla Institute For Allergy METHODS FOR IDENTIFYING AGENTS CAPABLE OF MODULATING PROTEIN KINASE C THETA (PKCυ) ACTIVITY

Also Published As

Publication number Publication date
IL175351A0 (en) 2006-09-05
JP2007525210A (ja) 2007-09-06
CA2545722A1 (en) 2005-07-14
NO20062496L (no) 2006-09-11
EP1702214A4 (en) 2007-12-19
EP1702214A2 (en) 2006-09-20
WO2005062918A2 (en) 2005-07-14
RU2006126704A (ru) 2008-01-27
MXPA06007094A (es) 2006-08-23
US20050164323A1 (en) 2005-07-28
AU2004308441A1 (en) 2005-07-14
BRPI0417212A (pt) 2007-02-06
ECSP066672A (es) 2006-10-25
KR20060127415A (ko) 2006-12-12
WO2005062918A3 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
CR8398A (es) Metodos para el tratamiento del asma
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
PA8608201A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular
MX2022005119A (es) Metodos de reduccion de olor.
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
DOP2022000060A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
UY29300A1 (es) Compuestos quimicos
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
AR059570A1 (es) Seleccion y estabilizacion de constructos de arn ds
CY1117683T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
ATE478092T1 (de) Verbesserte sekretion von neublastin
JP2003529374A5 (es)
PE20230179A1 (es) Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
GT200200014A (es) Inhibidores de piridina de metaloproteinasas de la matriz
AR024335A1 (es) Hialuronidasa de hirudinaria manillensis, aislamiento, purificacion y metodo recombinante de produccion
CL2008003449A1 (es) Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
NI200900028A (es) Inhibidores de la metaloproteinasa matriz
MX2023012605A (es) Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos.
MXPA05005545A (es) Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
PE20210811A1 (es) Acido ribonucleico bicatenario capaz de suprimir la expresion de c5 de complemento
MX2024000713A (es) Vectores policistrónicos para terapias a base de células.
MX2021015501A (es) Anticuerpos y metodos de uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)